BBUSvsIBB
JPMorgan BetaBuilders U.S. Equity ETF against iShares Biotechnology ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BBUS | IBB | |
|---|---|---|
| Expense ratio | 0.020% | 0.44% |
| Assets | $9.7B | $11.1B |
| Net flow, 1 month | +$356M | −$73M |
| Net flow, 1 year | +$2.7B | +$1.2B |
| Return, YTD | +8.1% | +23.2% |
| Return, 1 year | — | — |
| Avg daily volume | 307K | 2M |
| Holdings | 469 | 243 |
| Listed | Mar 11, 2019 | Feb 5, 2001 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS